
|Articles|June 20, 2019
Dr. Adi Diab on Baseline Tumor Immune Signatures and Therapy Response in Solid Tumors
Author(s)Adi Diab, MD
Cancer Network spoke with Adi Diab, MD, of MD Anderson Cancer Center, on the link between baseline tumor immune signatures and response to bempegaldesleukin and nivolumab in patients with advanced solid tumors.
Advertisement
Cancer Network spoke with Adi Diab, MD, of The University of Texas MD Anderson Cancer Center, regarding the results of the phase I/II PIVOT-02 trial. He and fellow investigators are exploring the association between baseline tumor immune signatures and response to bempegaldesleukin (NKTR-214) and nivolumab in patients with advanced solid tumors. The results (
Advertisement
Latest CME
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Grants OncoSil Humanitarian Device Exemption in Distal Cholangiocarcinoma
2
CAR T-Cell Therapy Earns FDA IND Clearance in Large B-Cell Lymphoma
3
Bispecific Antibodies Are Advancing Into Earlier-Line Multiple Myeloma
4
eVOLVE-Lung02 Trial of Volrustomig Discontinued in Metastatic NSCLC
5





















































